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Introduction
Since the completion of the Human Genome Project, 
the marvel of the human genome has piqued the 
interest of the general public. Private companies 
cater to this interest by offering direct–to–consumer 
genetic testing (DTCGT) based on genome–wide 
evaluation of subtle differences in the genetic 
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Abstract. Background: Direct–to–consumer genetic testing (DTCGT) offers risk estimates for a variety of complex 
diseases and conditions, yet little is known about its impact on actual users, including their decisions about 
sharing the information gleaned from testing. Ethical considerations include the impact of unsolicited genetic 
information with variable validity and clinical utility on relatives, and the possible burden to the health care 
system if revealed to physicians. Aims: The qualitative study explored primary care patients’ views, attitudes, and 
decision making considerations regarding DTCGT. This article focuses on the disclosure decisions participants 
made regarding participation, testing, and results of DTCGT, a topic which arose as a secondary aim of the 
study. Methods: Through four longitudinal interviews (pre–test, results, 3 and 12 months post–test) we examined 
twenty primary care patients’ decisions, expressed intentions, and actions regarding disclosure to immediate 
and extended family, friends and coworkers, and physicians about participation in and results of DTCGT. 
Individual interviews were analyzed using qualitative content analysis and a summative approach to describe 
the global themes. Results: Most participants disclosed to some immediate family; less than half disclosed to 
extended family; approximately half talked to friends. Most participants stated they would or might disclose 
to physicians about DTCGT and a few did. Conceptual themes that emerged from the data analysis include 
ambivalence about disclosure, consistency between intention and actual disclosure behavior and decisions, 
and conditional information sharing. Conclusions: Participants’ intentional and actual disclosure patterns offer 
insight into how they view DTCGT, weigh results, and the potential impact of DTCGT.
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sequence. DTCGT, which returns a wide range of 
genetic risk results with varying levels of analytic 
validity and clinical utility, offers a different model 
for obtaining genetic information than traditional 
clinical genetic testing, which is usually done for 
individuals identifi ed as at high risk for specifi c 
diseases (Wasson, Cook, & Helzlsouer, 2006; Was-
son, 2009). DTCGT offers risk evaluation for health 
disorders, physical traits, drug response, and carrier 
testing for Mendelian disorders. Due to the avail-
ability of DTCGT in the public arena, it is important 
to assess its impact on individuals, communities 
and wider society, which helps to inform appropri-
ate education, policymaking, and clinical practice.
One aspect of assessing the impact of DTCGT is 
disclosure decisions individuals make regarding 
testing and results. Disclosure, the focus of this 
article, has been addressed in the context of genetic 
testing for single–gene disorders, especially condi-
tions with high emotional and medical impact such 
as hereditary breast and ovarian cancer, fragile X 
syndrome, and Huntington’s disease (Forrest et al., 
2003; Forrest et al., 2008; Gaff et al., 2007; Klitzman, 
Thorne, Williamson, Chung, & Marder, 2007; Peters 
et al., 2011; Ratnayake et al., 2011). These studies 
address the content and accuracy of disclosure, 
to whom participants choose to disclose results 
of genetic testing, their concerns about disclosure, 
and effective communication practices. Ethical 
concerns have been raised about the impact of 
DTCGT on individuals, families, and health care 
providers as previous research indicated potential 
consumers would expect their physician to help 
them understand results, thus potentially bur-
dening the health care system if uptake of testing 
increases (McGuire, Diaz, Wang, & Hilsenbeck, 
2009; McGuire & Burke, 2008). In addition, deci-
sions made on the basis of inaccurate or unproven 
DTCGT information, including false positives or 
false negatives, have been raised regarding consum-
ers and could also apply to their blood relatives 
if results were shared (Wasson, Cook, & Helzl-
souer, 2006). Consumers could reveal unwanted 
or disturbing genetic information, e.g. regarding 
hereditary cancers or Alzheimer’s Disease, to rela-
tives without their “consent” or recognition of the 
potential consequences for the other. Yet, little is 
known about how actual users of DTCGT decide 
to whom and when to disclose this information, if 
at all. There are few published studies that address 
the details of disclosure choices regarding DTCGT 
participation and results in particular participants’ 
decision-making choices and reasoning over time.
Limited data are emerging regarding DTCGT 
disclosure or intent to disclose to family mem-
bers and/or physicians (Bloss, Schork, & Topol, 
2011; Gollust et al., 2012; Kaphingst et al., 2012; 
McGowan, Fishman, & Lambrix, 2010; O’Daniel, 
Haga, & Willard, 2010; Ormond et al., 2011; Gordon 
et al., 2012). The data from actual users of DTCGT 
are limited and do not paint a consistent picture. 
McBride, Koehly, Sanderson, & Kaphingst, 2010, 
state the necessity of research “characterizing 
patterns of information sharing among the social 
network” and that “methodologies that provide 
an understanding of the family social structure and 
how that structure affects and is affected by genetic 
information are needed.”
We conducted an exploratory, qualitative study 
of primary care patients’ attitudes and views about 
DTCGT, aiming to learn more about what factors 
or considerations infl uence their decision–making 
processes regarding whether or not to participate 
in DTCGT. The importance of disclosure decisions 
arose during data analysis. The act of disclosure is 
characterized as how participants use and dissemi-
nate DTCGT information, e.g. to whom participants 
reported talking about the DTCGT research, testing 
or results. Our reasons for focusing on disclosure 
choices are three–fold. First, we aim to explore 
disclosure as a behavior or action that can be 
documented over time, monitoring intention and 
consistency in participants. Secondly, following 
disclosure patterns longitudinally offers insight 
into participant decision making, painting a more 
nuanced and detailed description of their processes. 
Disclosure directly refl ects part of participants’ 
motivation for pursuing DTCGT, and in some cases 
disclosure itself is a reason to pursue testing. Finally, 
we suggest that the act of disclosure is an identifi -
able indication of participant preferences. How par-
ticipants use and disseminate genetic information 
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helps us understand what they fi nd important—or 
on the other hand, insignifi cant—for themselves 
and/or their families. Understanding patient deci-
sion–making processes and preferences regarding 
DTCGT disclosure may inform those involved in 
genetics and primary care, and discussions in wider 
society about the impact of this testing.
Methods
Participants
This exploratory qualitative study was reviewed 
and approved by the Institutional Review Board at 
Loyola University Chicago. We targeted a primary 
care patient population for several reasons: (1) 
There was at the beginning of the study (August 
2009), and remains, a lack of published research 
on primary care patient decision making about and 
reactions to DTCGT; (2) This patient population 
offered insight into the decision making of a poten-
tially more diverse sample than early studies, which 
included social networkers and early adopters; (3) 
We hypothesized they might use their primary care 
physician as the gateway contact with the medical 
fi eld, particularly when receiving DTCGT results; 
and (4) Recruited participants would already have 
an identifi ed physician in case of medically relevant 
fi ndings.
The study was conducted in two phases. Phase 
One included four focus groups of patients recruited 
from a primary care waiting room at an urban aca-
demic medical center. Patients were approached in 
the waiting room, informed about the study, and 
asked if they would consider participation. Those 
answering “yes” provided contact information and 
were later re–contacted and invited to participate 
in a focus group. Eligibility criteria included being 
18 years old, English speaking, and not having had 
prior genetic testing (except for standard pre–natal 
genetic screening, which is widespread). A total of 
twenty–nine primary care patients participated in 
this phase and results are reported elsewhere (Was-
son, Hogan, Sanders, & Helzlsouer, 2012). Here, we 
report results from Phase Two (December 2009 to 
June 2011), in which twenty participants provided 
informed consent for research and testing, under-
went DTCGT, received results and participated in 
two additional follow–up interviews. All partici-
pants from Phase One were informed of Phase Two 
after each focus group and asked if they would con-
sider participating. Sixteen participants (55%) from 
Phase One chose to undergo DTCGT in Phase Two; 
four additional participants were recruited directly 
from the primary care waiting room. Based on other 
qualitative studies, we determined that 20 partici-
pants would capture a range of views and attitudes 
needed to reach data saturation (Madsen, Holm, & 
Riis 2007; Schmidt, 2010). Because almost half of the 
individuals who participated in Phase One chose 
not to undergo DTCGT, data from each phase are 
reported separately (Wasson, Hogan, Sanders, & 
Helzlsouer 2012; Wasson, Sanders, Hogan, Cherny, 
& Helzlsouer, 2013).
Data Collection
Data were gathered through four individual inter-
views occurring over approximately 12 months 
during the: 1) Informed consent session, where a 
saliva sample was provided for DTCGT; 2) Receipt 
of results 4–6 weeks after the informed consent 
session; 3) Three months post–results, and; 4) 
12 months post–results. Interviews one and two 
included a genetic counselor to answer questions 
and review results with the participant. In interview 
one, the genetic counselor fi elded questions about 
the nature of testing and the nuances of the consent 
documents. In interview two, the genetic counselor 
pointed out any increased risks listed in the results, 
and discussed the genetic etiologies of these fi nd-
ings and others, allowing the participant to explore 
their results pages and ask any questions.
All 20 participants provided a saliva sample for 
analysis after their individual informed consent ses-
sion, which included the study consent process and 
the 23andMe online consent form. The 23andMe 
test kit was used because it included a broad range 
of test types: carrier status for known single–gene 
conditions, common disease associations, drug 
susceptibility, and physical traits such as freckling 
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and earwax type. Further, these tests have widely 
varying clinical specifi city and results range from 
clinically actionable (e.g. BRCA mutations) to poten-
tially interesting but medically irrelevant (e.g. eye–
color or baldness). Lastly, the 23andMe kit was the 
least expensive DTCGT available at the time. The 
cost of testing ($299–499) was covered by the study.
At each interview, participants were asked open–
ended questions about reasons for participating 
in the testing, their decision to test, expectations, 
concerns about testing, and with whom they had 
or would discuss their participation and/or results. 
Interviews 3 and 4 (three and twelve months post–
results) also included questions on participants’ over-
all reaction to the testing process and whether testing 
had had any impact on them physically, emotion-
ally/psychologically, or on their relationships/fam-
ily, and lifestyle/behavior. They were also queried 
about their willingness to pay for and/or endorse 
this type of genetic testing. All twenty participants 
completed the fi rst three face–to–face interviews and 
17/20 completed the 12–month interview in person 
or by telephone. All interviews were audio recorded 
and transcribed verbatim. Participants received fi fty 
dollars and a parking pass for each interview.
This analysis focuses on responses to specifi c 
questions asked to capture participants’ intentions 
to disclose information about taking the DTCGT 
and actual disclosure decisions over time. Disclo-
sure patterns and decisions arose as a key area dur-
ing the data analysis as participants articulated and 
refl ected on their decisions and actions over time.
Data Analysis
Qualitative content analysis was used to analyze 
responses to specifi c disclosure questions. Con-
ventional content analysis is an inductive approach 
where the researchers immerse themselves in the 
data and allow categories to emerge from partici-
pants’ own words, rather than imposing precon-
ceived categories on the data. Researchers also used 
a summative approach to gain a sense of the global 
trends in disclosure in the data (Hsieh and Shannon 
2005; Morgan 1993).
Two of the researchers (Sara Cherny and Kath-
erine Wasson) read all the interview transcripts 
to familiarize themselves with the data and made 
notes about potential categories for analysis. They 
used this initial reading to become familiar with 
the context in which the disclosure questions were 
answered. Next, they again independently read the 
specifi c disclosure questions in detail and identifi ed 
potential categories for recording to whom partici-
pants intended to and actually did disclose DTCGT 
participation and/or results at each interview. They 
then determined the fi nal categories (e.g. intention 
to disclose participation/results, may disclose, did 
disclose, did not disclose, will not disclose). Both 
researchers met in person and together re–coded 
each participant’s responses to the disclosure ques-
tions, resolving any differences in coding during 
this session. This process allowed the researchers 
to evaluate more clearly participants’ stated inten-
tions and actions about disclosure and emergent 
patterns over time.
In addition to specifi c categories of disclosure, 
i.e. to whom participants disclosed, overarching 
themes also emerged during the data analysis 
which shed light on why participants chose to (or 
not) discuss the testing and results with particular 
individuals or groups. Both researchers read the 
transcripts independently and met regularly to 
discuss the potential themes, resolve any discrep-
ancies, and agreed the fi nal themes for inclusion 
in the analysis. No qualitative software was used.
Results
Our sample was 50% African American, 50% Cau-
casian, and 60% female. Participants’ age ranged 
from 29 to 63 (average of 49.5 years), and 65% were 
married. The proportion of African Americans in 
our sample is higher than in the general population 
(12.6% per US Census website), and participants 
had lower education levels as compared with 
participants in other currently published studies 
on the impact of DTCGT (McGowan, Fishman, 
& Lambrix 2010; Kaufman, Bollinger, Dvoskin, & 
Scott, 2012; Bloss et al., 2010; O’Daniel et al., 2010). 
All participants were high school graduates; 30% 
had college or post–graduate degrees. Fifty–fi ve 
percent of participants carried private insurance, 
40% had Medicare or Medicaid, and 5% were unin-
sured (See Table 1).
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Table 1
Individual Testing
N=20  
Age  
Range 29–63
Mean/Average 49.5
Income  
Less than 5,000 10.00%
5,000–9,999 0.0%
10,000–24,000 30.0%
25,000–49,999 25.0%
50,000–74,999 15.0%
75,000–above 20.0%
Sex  
Female 60.0%
Male 40.0%
Education  
High School Grad 30.0%
Some College 40.0%
College Grad 25.0%
Post Graduate 5.0%
Marital Status  
Never Married 15.0%
Married 65.0%
Separated/Divorced 10.0%
Widowed 10.0%
Race/Ethnicity  
Black 50.0%
White 50.0%
Insurance  
Private 55.0%
Medicare/Medicaid 40.0%
None/Uninsured 5.0%
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The analysis of participants’ disclosure of DTCGT 
information revealed four groups of people in their 
social network to whom they may have intended 
to disclose or actually disclosed participation and/
or results of testing (See Figure 1). Circle 1 includes 
those in closest proximity to the participant and 
most likely to be affected by genetic health informa-
tion, i.e. their immediate family (spouse, children, 
parents, siblings). Circle 2 includes extended fam-
ily who might also be affected by genetic health 
information (aunt, uncles, cousins, grandparents, 
in–laws). Circle 3 includes friends, coworkers, and 
other non–family. Physicians were considered and 
analyzed separately as they are not blood relatives 
and may not be “close” to the participant. Due to 
the physician’s role in maintaining the patient’s 
health and wellbeing, participant choices regarding 
disclosure of DTCGT results to him or her may be 
different from their choices regarding their family 
and social network.
For the analysis of disclosure behaviors here, 
interviews 1–2, the informed consent and initial 
results session, are usually grouped together, 
and interviews 3–4, which were 3 and 12 months 
post–results are grouped together. Participants 
did not have the opportunity to report whether 
they revealed results to anyone until interview 3, 
though they could have mentioned participation 
in the study. Overall, by interviews 3–4, almost all 
participants (19) had talked to some immediate 
Figure 1 Family and social networks.
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family (Circle 1); only one participant talked to no 
one. Some (six) only talked to those in Circle 1 and 
for a few, this meant only their spouse (3). In addi-
tion, some (seven) disclosed to extended family and 
approximately half of all participants (11) talked 
to people in Circle 3. A majority of participants 
disclosed to immediate family and friends, while a 
minority disclosed to extended family. Only a small 
number of participants (fi ve) talked to people in all 
three circles.
Disclosure to Family
Disclosure to family included the fi rst two circles 
in the analysis. Over half of participants reported 
being married, and all of these reported sharing 
both participation and results with their spouse. 
Most participants expressed an intention to disclose 
information about participation in DTCGT to others 
in Circle 1 in addition to a spouse during interviews 
1–2, and all but one did disclose to immediate fam-
ily members by interviews 3–4. For example, this 
participant noted in the fi rst interview that disclos-
ing to family was intended and would be important.
Defi nitely, defi nitely the family. We are so close 
knit of a family. We talk about everything and 
in the group discussion with the people that I 
had a couple weeks ago, I was talking about 
how it would be good if you defi nitely talked 
with your family. A lot of people were kind of 
against that, a little shady on it, and I thought, 
well, if you share with your family something 
may come up and they will tell you, “Well hey, 
you know, your great, great aunt had this and 
you know you never knew about it,” so when 
you talk with the family things do come up that 
would actually help you and your family and 
your kids and their kids. So, defi nitely will share 
it with my family. (Participant 12: Interview1)
Regarding Circle 2, some participants (seven) 
indicated by interview 4 that they had talked to dif-
ferent extended family members about their experi-
ence with DTCGT. Interestingly, only approximately 
half of this group had indicated a prior intention to 
disclose to extended family in interviews 1 and 2. 
Nearly twice as many participants reported talking 
to extended family after receiving results versus 
prior to testing. A few participants (three) demon-
strated a lack of intention to disclose participation 
or results beyond their spouse and did not.
Disclosure to Friends and Coworkers
While only some (seven) participants noted an 
intention to disclose their participation to Circle 3 
during interviews 1–2, a majority (12) had talked 
about participation or results with them by inter-
views 3–4. For example, this participant reported 
talking to multiple people about DTCGT.
Oh, everybody that knows I’m coming here 
today. Monday at work, with my wife and a 
couple of my friends that I’ll see over the week-
end that I’ve told I was doing this. They all fi nd 
it very interesting, they really do. (P6:I2)
Some (eight) chose not to disclose results to 
friends or co–workers, noting the information was 
personal and not necessary or appropriate to dis-
cuss with others.
They weren’t family and they weren’t my doctor 
. . . I fi gured my results for something like that 
is personal. (P11:I4)
Disclosure to Physicians
During interviews 1–2, less than half (eight) of 
participants expressed an intention to discuss 
participation and/or results with their physician 
in response to an open–ended, general question 
about disclosure; a specifi c prompt for disclosure 
to physicians was included in interview 3. Of those 
expressing intent to talk to their physician, all but 
one did disclose by interview 4. An additional eight 
participants said they might disclose participation 
or results to their physician (interviews 1–3) and 
only one did. A few (four) participants expressed 
no intention to talk to their physician about par-
ticipation in DTCGT and only one did disclose by 
interview 4.
Participant Disclosure Themes
The data analysis revealed three overarching themes 
that were signifi cant in capturing participants’ 
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intentions and actions regarding disclosure across 
the different groups. These included ambivalence or 
nonchalance about disclosure, consistency between 
intention and actual disclosure behavior and deci-
sions, and conditional information sharing.
Ambivalence and Nonchalance about 
Disclosure
Several of our participants expressed ambivalence 
or nonchalance about disclosure of their results, 
especially to physicians. Ambivalence is refl ected 
in the difference between those indicating they will 
(intention) or might discuss participation and/or 
results with physicians and actual disclosure to 
physicians by interview 4. Sixteen of the twenty 
stated by the third interview that they would or 
might tell their doctors about their participation 
or results at some point in the future. By the fourth 
interview (12 months post–test), only half (eight) of 
these had shared results with their physician; the 
majority of these had expressed a clear intention 
to do so earlier.
In the third and fourth interviews, some par-
ticipants explained that they had not had an 
opportunity or reason to see their doctor, and one 
participant simply forgot. No participant reported 
making an appointment with a physician specifi -
cally to discuss participation in or results of DTCGT. 
No participant stated that their test results were 
concerning or signifi cant enough to have an emo-
tional or psychological effect on them. At the fourth 
interview, some participants did not remember 
what their results were.
I haven’t spoke to them at all . . . I don’t go to 
the doctor’s offi ce that much. . . . Probably, I 
probably will. Not saying that I won’t, you 
know, but it might come up in a conversation 
you know. (P10:I3)
I have not. I haven’t seen my primary care 
physician, and I don’t know that I will. When I 
went to the website to see about this particular 
one I thought even if my kids do have it now, 
from what, which I don’t think they do, but all 
they can do at this point seems to be the same 
kind of healthy living practices that we do, so I 
don’t know that there’s a need for that. I might 
mention it to my primary care physician just 
that I had the test or was in the research study 
or something. (P4:I3)
Ambivalence was more diffi cult to assess with 
regard to family and friend circles. There did not 
seem to be the same pattern of having intent to 
disclose and then not doing so. On the contrary, 
participants seemed to disclose to various members 
of their social circles without having previously 
demonstrated intent to do so.
Consistency
For a minority of participants, their intent and 
actions were clearly consistent regarding physi-
cians: all participants who had shared results with 
their physicians by the third interview had stated 
their intent to do so in the fi rst and/or second 
interviews. One participant clearly noted in the 
fi rst interview that he would share the results with 
his physician. He did so by the third interview, 
although it seems he wanted more time spent on 
the results:
 (First interview) When I get the results of this I 
will bring the results over to my general practi-
tioner regardless of what . . . (P16:I1)
(Third interview) Well I briefl y mentioned it 
to my doctor . . . I’m not sure if it was really 
discussed to the full extent. So he took a 
quick copy of it and it was put in the fi le. Of 
its worth for the information, I’m not sure if 
it was actually used to the full extent. If I had 
more time I could have, or we may have, I 
don’t know. (P16:I3)
Three participants said they had no intent to discuss 
participation or results with their doctors, and none 
of them did disclose to their physicians.
Regarding intention and disclosure to imme-
diate family, participants were overwhelmingly 
consistent. Most expressed the intention to disclose 
to someone in Circle 1 early on and then stated 
that they did during later interviews. Regarding 
extended family, the picture is more inconsistent. 
Only half of participants who reported disclosing 
to them in interviews 3–4 had indicated an inten-
tion to do so in interviews 1–2. When comparing 
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intention to actual disclosure to someone in 
Circle 3, friends and coworkers, the picture is also 
inconsistent. Again, only half of the participants 
who reported telling this group by interview 4 
had stated an intention to talk to them in earlier 
interviews.
Conditional Information Sharing
For some participants, the motivation to share infor-
mation was in some way conditional, in that their 
disclosure would depend on the nature, content, 
perceived impact, and/or perceived clinical util-
ity of the DTCGT information. This conditionality 
applied both to decisions to disclose and not to 
disclose, and to disclosures to individuals within 
family, social circles and physicians.
Results content
For some participants, the content of results was a 
key factor in weighing their decisions to disclose 
or not. In the fi rst interview, one participant stated 
that disclosure would depend on the result content 
as well as whom the results might affect:
Well it all depends on what the results say. I 
mean, if it’s something that is a defi nite that 
could possibly be something in the future as far 
as just affecting me, then probably not. But if it’s 
a marker that can say, well it’s genetic linked 
and it can be given down the line, then I prob-
ably will. You know if I start to see symptoms 
within the kids I probably will make mention, 
but right now just because everything is so fairly 
new, I probably wouldn’t go into details right 
now. (P3: I1)
This same participant, after seeing her results, stated 
that the questionable accuracy and low impact of 
the results were a reason to not disclose:
I probably won’t, because it was nothing really 
to discuss . . . nothing showed up, so it probably 
wouldn’t be worth mentioning. I mean, down 
the line if something like this comes available 
again and, you know, they say that it’s a 100% 
proof that this is what this is, and this is because 
of this, then I may partake in something like that 
again just to have a defi nite answer to say yes, 
this is because of family history and this is what 
your risks may be. But because this is something 
preliminary, it’s like not even worth mentioning 
at this point I don’t think. (P3:I2)
Participants who had children sometimes com-
mented on the benefi ts and limitations of sharing 
results with their children. For example, when asked 
with whom she might discuss results in the future, 
one participant said “my two children and probably 
my mom, it all depends” and then clarifi ed:
I have to hear what the results are. Most likely 
whatever it—I’ve been through worse—so what-
ever it is I believe I will discuss it with them. My 
daughter kind of takes things kind of hard, so 
that’s why I said maybe. My son may be more so 
than her. I would have to see. But I’m believing 
in good results, good results from that. (P8:I1)
Being a breast cancer survivor and having two 
teenage daughters I thought that any informa-
tion that I could glean from the testing would 
be important, and that was primarily the reason 
why I did it. (P15:I3)
Infl uence of anticipated response
In weighing whether to disclose DTCGT infor-
mation, some participants discussed how they 
expected the other person would perceive the 
DTCGT information, whether positively or nega-
tively, or if they might fi nd it useful.
. . . I discussed it with my husband and he 
agreed, he says you have nothing to lose, you 
have nothing to lose, you have more to gain 
just, you know, just to fi nd out what’s what 
since these things do run in your family and 
how high of risk are you for these diseases or 
different types of things. So he suggested it. 
My daughters, I talked to them about it to. I let 
them know, you know, what my fi ndings were 
and they said this is good, something they may 
want to do in the future. (P14: I3)
A few participants chose not to disclose based 
on an anticipated negative response from others.
They don’t even know that I’m even here doing 
the second one because my step daddy you 
know he’s a big jokester, he jokes a lot, he said 
he wouldn’t do it so I don’t think I want to talk 
to him about it, because I don’t want him to get 
my mom nervous or nothing like that, so I didn’t 
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talk to nobody about this one here so they don’t 
even know I’m here. (P1:I1)
Others anticipated that the response of their family 
members to the results would be positive.
My mother, interestingly enough, who is 95 
years old said, “oh I’m so glad you’re doing 
it.” Well this is typical of her, but, “I’m so 
glad you’re doing it, you’ll have to tell me the 
results.” (P4:I2)
Of course my family knows. We have several 
chronic disorders in my family that I think are 
genetic or have a genetic component and I think 
everybody just agreed that “Hey, if you have a 
chance to do this, do it and fi nd out what you 
can fi nd out.” (P4:I1)
Infl uence of Risk Perception
Another factor that affected disclosure choices was 
the participant’s perception of the risk of develop-
ing the diseases addressed in the DTCGT results. 
Some participants had specifi c health or disease 
risk concerns, such as heart disease, cancer or dia-
betes, while others were more broadly concerned 
with receiving “bad” or high risk results. For a few, 
results showing little to no risk of disease, or “good 
results”, decreased their likelihood of disclosure. 
After receiving her results, one participant said:
Probably no one. I don’t think that there was 
anything that was, that I feel that I need to go 
home and say, “Oh,” you know. (P18:I2)
For others, low risk estimates in results increased 
their likelihood of disclosure because they could 
reassure family that they were not at high risk for 
developing diseases:
When I go home I’ll discuss it more with my 
husband and then, you know, talk to maybe my 
mom . . . she’s not very optimistic. So this way I 
can tell her, “Look, I’m fi ne.” (P2:I2)
 . . . I think I stated the last time, I mean since 
because I’m the guinea pig, so–to–speak of the 
family, it’s like I didn’t want to alarm them ahead 
of time and then have everybody on pins and 
needles waiting on results. I shared with my 
brother after the fact and after I got the results and 
everything was clear I brought it to their attention 
that there’s something they need to be doing as 
far as for themselves and their kids and wife. 
Everybody needs to do it, period. I mean I really 
strongly think still it needs to start at birth and just 
have it in their fi le from birth. I mean I strongly 
believe that. I mean that way it will narrow down 
any type of problems if it’s done at birth. (P13:I3)
Clinical Utility
Decisions about disclosure to physicians were 
sometimes related to a family history of disease, 
or if the testing identifi ed specifi c areas of health 
concern. Some participants perceived that sharing 
the results with their physicians could help their 
care directly or prophylactically.
Oh I will, defi nitely just for his opinion. . . . he’s 
very thorough, and just to get his opinion and 
let him know that that information is there if I’m 
ever going to need it for whatever reason. But I 
will tell him. (P6:I2)
Only a few participants viewed their results as 
clinically useful. For example, a result showing 
increased sensitivity to the drug Warfarin increased 
the desire of a participant to share the results with 
her physicians:
To help them be able to treat me better medically, 
and one of the tests showed sensitivity that my 
primary care quickly put on my medical profi le 
because he’s never seen it, but if it ever happens 
he’s glad to know. (P7:I3)
Some participants gave specifi c reasons why they 
decided not to share the results with their doctor 
including the results not showing new or concern-
ing health information.
Because it said that I didn’t have anything wrong 
so I didn’t. (P2:I3)
I think it was important, you know, but it wasn’t 
anything I think that he already didn’t know so 
I didn’t bring it up to him yet. (P8:I3)
Participants intending to talk to their doctor 
generally expressed confi dence in their physicians’ 
ability to incorporate the results in to their care plan.
There’s all the little aspects of it, so if it’s some-
thing that could be used, why not? It’s just like 
other tests, it’s like a CAT scan or an MRI, we 
would use it. That’s all. (P16:I3)
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The reality of talking with their physician was 
somewhat different. For example, one participant 
expressed confi dence in her physician’s ability to 
use the test results during her third interview. In the 
fourth interview, after she had discussed the results 
with her physician, she expressed disappointment 
in her doctor’s reaction:
After the test when I had like a physical, I had 
mentioned like I had these screenings, these 
tests, the study done. And it seemed like she 
just sort of brushed it off. (P14:I4)
Of the eight participants noting they had minor 
children, three participants, all female, felt that 
the results would be clinically relevant for their 
children. They all stated that they would speak 
or were considering speaking to their children’s 
physician, independent of their choice about dis-
cussing the results with the children themselves. 
For example, one stated that she would discuss it 
with her children “when and if they’re ready, but 
with their primary care, yes.” (P7:I2)
Another was considering it:
Stuff that comes back where you are more likely 
to get this and there is something that I have 
passed on, I don’t want the children to know. 
Maybe the doctor, like maybe their pediatrician 
should know. (P9:I1)
Discussion
This study highlights disclosure decisions in pri-
mary care patients undergoing DTCGT. Participant 
decisions about disclosure seem to depend on mul-
tiple factors—the type of information anticipated 
and provided, the actual results, personal reaction 
to DTCGT information, and perceived reaction to 
results by others. Participants talked to a variety of 
people, including immediate and extended fam-
ily members, as well as non–family members and 
physicians.
Some of the parties to whom participants 
disclosed would potentially be at risk for the 
same conditions identifi ed as risk factors for 
the participant. One individual participating in 
DTCGT could lead to further interest in or actual 
testing of family members. If based on unreliable 
or inaccurate DTCGT results, there could be 
unnecessary anxiety for relatives or unnecessary 
cost to the patient and health system. In addition, 
the participant could reveal unwanted health 
information, e.g. about hereditary cancers or 
Alzheimer’s Disease, to relatives without their 
full understanding of or desire to obtain that 
information.
For example, family cascade testing is common 
in genetic counseling practice for families in which 
an individual has been identifi ed as having a spe-
cifi c disease risk or genetic condition. Targeted test-
ing is systematically offered to subsequently more 
distant family members from the original tested 
individual. The resulting cascade could have posi-
tive or negative impact on those individuals and/
or the health care system depending on the results 
and risk estimates given, personal and professional 
interpretation of results, and any subsequent actions 
taken by the tested individual(s) and/or their 
physician(s). The potential effect of DTCGT relates 
to the statement made by McBride and colleagues 
(2010) regarding the need for understanding of 
kinship networks. It will be important to identify 
more clearly these various familial and communal 
disclosure patterns to evaluate further the impact 
of DTCGT on individuals, their social networks, 
physicians, the health care system, and society 
more broadly.
Ambivalence/Nonchalance
In our study, ambivalence regarding disclosure 
was most evident with regard to disclosure to 
physicians. Other studies have addressed physician 
disclosure within their populations. Gollust and 
colleagues (2012) and Bernhardt and colleagues 
(2009) found high levels of intent in their respective 
populations: 92% and 96% of potential DTC genetic 
testers predicted they would talk to their doctors 
about their results. In comparison, less than half 
(8/20) of our sample expressed specifi c intent to 
disclose participation in and/or results of DTCGT 
with their physicians at any point in the study. Only 
fi ve of our participants clearly indicated intent to 
disclose to their physicians in the fi rst interview, 
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prior to testing (and did so). Additionally, less 
than half (8/20) said they might disclose to their 
physician, and of those, 6 had not by the time of 
Interview 4. Thus, we are cautious when comparing 
our participants, having used DTCGT as part of the 
study, to potential users of DTCGT who have not 
(yet) proceeded with testing, as there seems to be a 
gap between intent to disclose and actual disclosure 
decisions after testing.
With regard to actual disclosure of results, 
reported fi ndings are varied. Our fi ndings are 
most comparable to that of the Coriell Personal-
ized Medicine Collaborative (CPMC) participants, 
where 25/60 spoke to a physician by the time of 
their interview and 14 more indicated intent to 
disclose in future (Gordon et al., 2012). Kaufman 
and colleagues (2012) reported that 28% of their 
population of DTCGT users talked to at least one 
healthcare professional, and 20% shared results 
with their primary care physician. O’Daniel and 
colleagues (2010) and Kaphingst and colleagues 
(2012) offer more dramatic examples, with 0% 
and 1% of their respective samples having spoken 
with a physician three months after participat-
ing in DTCGT or genetic susceptibility testing. 
It is important to note that there seems to be a 
signifi cant difference between the intentions of 
potential users and the intentions and disclosures 
of actual users of DTCGT both in our study as 
well as in others. Our longitudinal format and 
qualitative analysis, allowing for investigation 
of both intended and actual disclosure decisions 
and choices pre–and post–test, may demonstrate 
a more nuanced participant thought process with 
regard to physician disclosure than previous 
studies.
If this general ambivalence is applicable to a 
broader population, it could inform the discus-
sions about the potential burden on physicians 
from this type of testing and the necessity of medi-
cal professional involvement in DTCGT (Howard 
& Borry, 2012; McGuire & Burke, 2008). If results do 
not have a signifi cant impact such that participants 
are not reporting them to their physicians or seek-
ing help interpreting them, then there may not be 
a marked increase in physician time demands or 
additional testing and burden on the health care 
system as a result of DTCGT being available to the 
general public (Giovanni, 2010). It is important 
to reiterate that our participants received genetic 
counseling as part of their testing process, as the 
investigators viewed it as a necessary and ethical 
part of practice, which may have affected their 
desire to seek advice or recommendations from 
a physician, or simply to share their participa-
tion and/or results. If their reaction is because 
the genetic counseling played a signifi cant role, 
then the fi ndings identify a need for that process. 
Therefore, while there may not be an increased 
burden on physicians from DTCGT, there would 
be on genetic counseling services, which would 
not necessarily be included in DTCGT. Alterna-
tively, participants may have received closure on 
or answers to their genetic susceptibility questions 
from the testing and, therefore, did not feel the 
need to discuss it further with physicians or other 
health professionals.
Conditional Information Sharing
Clinical Utility
For those participants who expressed ambivalence 
regarding their potential information sharing 
about DTCGT, we speculate that it may be related 
to their perception of clinical utility. Few partici-
pants reported fi nding their results clinically use-
ful; some stated that the results were consistent 
with what they already knew about themselves 
or their families, e.g. increased risk for heart 
disease, or diabetes. If there was nothing new or 
interesting to learn from the results, participants 
may have been less likely to disclose them. Also, 
we think that participants might have different 
privacy expectations in relationships with family 
versus non–family. Disclosure choices may relate 
to varying levels of trust participants had in oth-
ers with regard to how the discloser might want 
the information used. Participants who did not 
tell their physicians may not have trusted them 
with this type of information because of their 
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patient–physician relationship, previous experi-
ence in the health care system, or fear of genetic 
information in their medical record having impli-
cations for insurance coverage (Wasson, Hogan, 
Sanders, & Helzlsouer, 2012).
Consistency
The consistency between intention and actual 
disclosures to immediate family was notable. This 
information sharing is understandable because 
participants have regular contact with immediate 
family, providing the opportunity to talk about 
their experience with DTCGT, and they may also 
have thought that the testing might impact these 
family members more directly. In contrast, the 
patterns of intention and disclosure with extended 
family are inconsistent. Only half of participants 
who reported disclosing to them in interviews 3–4 
had indicated an intention to do so in interviews 
1–2. This situation may be because participants 
have less contact with extended family or are not 
as close to them as immediate family. It may also 
be related to the participant’s intent with regard 
to participation in the study itself—if the partici-
pant was not seeking health information for his/
her family, then there may not have been a strong 
impetus to reach out specifi cally to extended fam-
ily members. It is worth considering further the 
implications of this disclosure pattern. Extended 
family was not necessarily alerted to the fact that 
the participant was undergoing DTCGT. If the 
participant had been given results which could 
or did affect family, extended family did not have 
the opportunity to consider the implications of 
or express their wishes regarding being told or 
not told the results. They were simply told about 
testing and/or results after the fact. For example, 
a cousin may not have wanted to know breast 
cancer results, but been unable to decline to know 
because the participant decided to share informa-
tion post–results and without consultation before 
the disclosure.
Regarding Circle 3, friends and coworkers, there 
were twice as many participants who reported tell-
ing this circle by interview 4 than had expressed an 
intention to do so earlier. This fi nding might sug-
gest that participants were unsure or ambivalent 
about what the testing would uncover. Once they 
received results, many saw them as not concerning 
and may have then felt more able to discuss the 
testing or results with friends. The results were 
perhaps viewed as non–threatening; instead they 
may have been seen as insignifi cant, recreational, 
or a novelty. We found it interesting that the 
breadth of disclosure to participants’ social and 
family networks increased from their initial inten-
tion and that more talked to friends than extended 
family. We considered that participants might 
see friends more often than extended family as a 
reason that a majority of participants were willing 
to discuss this novel type of testing with friends 
over time. These patterns of disclosure may also 
suggest that views on risk of a privacy breach of 
genetic information are varied. Some participants 
were nonchalant about disclosure and others were 
clear they would not disclose to different circles. 
Further research is needed in larger populations 
to investigate these varied views and examine 
why and to whom participants of DTCGT choose 
to disclose.
Regarding physicians, participants who noted 
their intention to disclose to their doctor early on 
(interviews 1–2) did disclose, except for one per-
son. This group was clear they wanted to tell their 
physicians about the testing and results. They were 
keen to get feedback from their physician, explore 
potential benefi ts of the DTCGT information now or 
in future, and trusted their physician to understand 
the results. They may have expected the physician 
to be more receptive or helpful, as some expressed 
disappointment in the reaction of their physician to 
1 The version of direct–to–consumer genetic testing offered 
by 23andMe and used in this study is not currently avail-
able.  The United States Food and Drug Administration is 
reviewing the tests and their reliability and accuracy and 
has requested the company cease to offer them to the public 
during that process. 23andMe continues to offer genetic 
ancestry testing direct–to–consumers.
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their disclosure or lack of attention paid to them. 
Similarly, most of those participants who were clear 
in early interviews that they would not tell their 
physicians did not. They were clear that they did 
not see a benefi t or wish to have the information 
enter the medical realm.
In contrast, most of the participants who were 
unsure or ambivalent about talking to their physi-
cians had not disclosed to them by interview four. 
This choice may be due to the fact that they were 
not worried about results, did not view results as 
“bad”, knew the tests were new and had variable 
accuracy and reliability, or had had their questions 
answered by the researchers or genetic counselor. 
Any or all of these factors may have infl uenced 
their decision not to disclose DTCGT or results to 
their doctors.
We hypothesize that there is more insight to be 
gained on the topic of consistency in intent and 
actual disclosures about DTCGT in a larger popula-
tion, which could lead to further categorization and 
predictive ability.
Limitations of this Study
In evaluating our fi ndings, it is important to note 
that this is a self–selected group of participants, 
and results are self–reported by them. Primary 
care patients who were willing to participate in this 
research may not be representative of other primary 
care patients. The cost of testing was covered by 
the study and the availability of free testing may 
have had an infl uence on participants’ decisions to 
participate. The cost of testing with 23andMe has 
been as low as $99 since the study was completed, 
which may make cost less of a factor in uptake.1 
In addition, genetic counseling was provided to 
participants, which may have affected their disclo-
sure decisions, particularly regarding physicians. 
Sixteen of the participants recruited for Phase 2 
had participated in a Phase 1 focus group during 
which they had the opportunity to participate in a 
discussion of the issues surrounding DTCGT, which 
could introduce a bias.
When reporting retrospectively, participants 
were not always specifi c about the content of their 
disclosures, i.e. whether they disclosed participa-
tion and/or results to others. We reported specifi c 
data when we had consistent detail from a particu-
lar group of participants or category of people to 
whom they disclosed.
A qualitative, longitudinal perspective allows 
increased insight in to the process of decision–mak-
ing and disclosure; however, it will likely be nec-
essary to assess these actions over an even longer 
time frame and on a larger sample to assess more 
fully the impact of DTCGT and results on disclosure 
decisions and actions. Our fi ndings are preliminary; 
further research is necessary to apply this informa-
tion to a wider population.
Conclusions
In this study we explored and noted that disclo-
sure intentions, decisions, and actions regarding 
DTCGT are carefully considered by participants, 
and they are willing to share the nuances of selec-
tive disclosure with researchers. It is possible to 
identify characteristics and considerations amongst 
our participants—consistency, ambivalence, reac-
tions of others, content of results—that impact 
disclosure decisions, and might apply to or provide 
clues about a broader primary care population. 
Disclosure patterns may help assess the likelihood 
of uptake of DTCGT by members of a participant’s 
social and family networks. They may also offer 
insight regarding the ethical issues for relatives 
who may receive unsolicited genetic information 
from participants and the potential burden upon 
physicians, genetic counselors, and the healthcare 
system of such information. In analyzing partici-
pants’ disclosure patterns, this study offers insight 
into how they view the privacy of their DTCGT 
information. It will be necessary to evaluate further 
primary care patient intentions and actions to assess 
the potential long–term impact of DTC genetic test-
ing on individuals, their families, communities, the 
health care system, and wider society.
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